Atrovent Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

atrovent

boehringer ingelheim (nz) limited - ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous - aerosol inhaler, metered dose - 20 mcg/dose - active: ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous excipient: citric acid ethanol nitrogen norflurane purified water - atrovent is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema and asthma.

Dixarit Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

dixarit

boehringer ingelheim (nz) limited - clonidine hydrochloride 25ug - tablet - 25 mcg - active: clonidine hydrochloride 25ug excipient: acacia amylodextrin calcium hydrogen phosphate dihydrate carnauba wax colloidal silicon dioxide indigo carmine   lactose monohydrate macrogol 6000 magnesium stearate maize starch methyl hydroxybenzoate povidone   propyl hydroxybenzoate purified talc sucrose titanium dioxide white beeswax

Imukin Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

imukin

boehringer ingelheim (nz) limited - interferon gamma-1b 200 µg/ml - solution for injection - 3 miu/0.5ml - active: interferon gamma-1b 200 µg/ml excipient: mannitol polysorbate 20 sodium succinate succinic acid water for injection - imukin is indicated as an adjunct for reduction of the frequency of serious infections in patients with chronic granulomatous disease (cgd). the benefits of imukin have been most marked in children with cgd although imukin may be used in adult patients.

Metalyse Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

metalyse

boehringer ingelheim (nz) limited - tenecteplase 30mg (recombinant) - powder for injection - 30 mg - active: tenecteplase 30mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

Metalyse Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

metalyse

boehringer ingelheim (nz) limited - tenecteplase 40mg (recombinant) - powder for injection - 40 mg - active: tenecteplase 40mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

Metalyse Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

metalyse

boehringer ingelheim (nz) limited - tenecteplase 50mg (recombinant) - powder for injection - 50 mg - active: tenecteplase 50mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

Mobic Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

mobic

boehringer ingelheim (nz) limited - meloxicam 7.5mg - capsule - 7.5 mg - active: meloxicam 7.5mg excipient: lactose monohydrate magnesium stearate maize starch sodium citrate dihydrate

Mobic Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

mobic

boehringer ingelheim (nz) limited - meloxicam 7.5mg - tablet - 7.5 mg - active: meloxicam 7.5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium citrate dihydrate - · symptomatic treatment of painful osteoarthritis (arthrosis, degenerative joint disease). · symptomatic treatment of rheumatoid arthritis. in patients for whom longer-term use may be required, treatment efficacy should be reviewed within the first month of treatment and mobic withdrawn if there is a lack of therapeutic benefit. patients on long-term treatment should be reviewed regularly, such as every three months with regards to efficacy, risk factors and the ongoing need for treatment. the decision to prescribe a selective cox-2 inhibitor should only be made after assessment of the individual patient's overall risk for developing severe adverse events e.g. history of cardiovascular, renal, or gastrointestinal disease, and after use of alternative therapies such as non-pharmacological interventions and simple analgesic therapy where these have been found to lack analgesic efficacy or to have unacceptable adverse effects.

Persantin Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

persantin

boehringer ingelheim (nz) limited - dipyridamole 25mg - tablet - 25 mg - active: dipyridamole 25mg excipient: magnesium stearate - indicated as an adjunct to oral anticoagulation for the prophylaxis of thromboembolism associated with mechanical prosthetic heart valves.

Persantin PL Perlongets Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

persantin pl perlongets

boehringer ingelheim (nz) limited - dipyridamole 150mg;   - modified release capsule - 150 mg - active: dipyridamole 150mg   excipient: acacia acetone dimeticone ethanol gelatin hypromellose hypromellose phthalate isopropyl alcohol methacrylic acid copolymer povidone purified talc purified water stearic acid tartaric acid triacetin